A Phase 2 Study of Tigilanol Tiglate in People With Soft Tissue Sarcoma

Full Title

A Phase IIa Open Label Study Evaluating the Preliminary Efficacy of Intratumoural Tigilanol Tiglate in Advanced and/or Metastatic Soft Tissue Sarcoma of the Extremities and Body Wall

Purpose

In this study, researchers want to learn if tigilanol tiglate is safe and works well against advanced soft tissue sarcoma. When injected into a tumor, tigilanol tiglate stops the blood supply to the cancer, which starves the tumor of nutrients. It may also make the immune system target and kill cancer cells.

Contact

For more information and to see if you can join this study, please contact Dr. Edmund Bartlett’s office at 212-639-2448.